Nama's AI scorecard currently rates STERIS Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is STE's P/E ratio?

STERIS trades at a trailing price-to-earnings ratio of 23.2.

When does STE report earnings?

STERIS's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $2.80.

What is the STE price target?

The median analyst price target from 7 analysts is $269.00, with a range of $232.00 – $275.00.

Is STE Shariah compliant?

Nama's AAOIFI-style screen reads STERIS as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does STE pay a dividend?

Yes — STERIS's dividend yield is 1.1%.

Nama Insights

STERIS (STE)

Healthcare · Medical Devices · NYSE

S&P 500

STERIS (STE) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $24.60B, a trailing price-to-earnings ratio of 23.2 and a free-cash-flow yield of 3.9%. Over the most recent reported fiscal year, revenue grew 8.7% and free cash flow per share grew 25.4%. Nama's AI scorecard rates it Buy, 6.9 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -19.4% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-6.4%

How far the last close sits under the highest price of the past five years.

Market cap	$24.60B
Trailing P/E	23.2
Price / book	3.4
Price / sales	4.1
FCF yield	3.9%
Dividend yield	1.1%
Gross margin	44.4%
Operating margin	18.9%
Net margin	13.3%
Revenue growth (YoY)	+8.7%
Revenue growth (3-yr annual)	+9.4%
EPS growth (YoY)	+10.2%
FCF/share growth (YoY)	+25.4%
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

STE earnings

Next report: Feb 3, 2027 (Q3 2027, EPS estimate $2.80). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2027	Nov 4, 2026	$2.94	$2.68	+9.7%	$1.59B
Q1 2027	Aug 5, 2026	$2.59	$2.49	+4.0%	$1.49B
Q4 2026	May 11, 2026	$2.83	$2.85	-0.7%	$1.59B
Q3 2026	Feb 4, 2026	$2.53	$2.53	+0.0%	$1.50B

STE analyst price target

Median target $269.00 from 7 analysts, ranging $232.00 – $275.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live STE data on Nama Insights →

Recent Congressional trades

STERIS trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Kevin Hern	House	Sell	$15,001 - $50,000	Sep 25, 2026
April McClain Delaney	House	Sell	$100,001 - $250,000	Sep 9, 2026
Jared Moskowitz	House	Sell	$1,001 - $15,000	Aug 27, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Aug 3, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Aug 3, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Aug 3, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Aug 3, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	May 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	May 8, 2026
April McClain Delaney	House	Buy	$1,001 - $15,000	May 6, 2026

STE FAQ

Is STE a buy?: Nama's AI scorecard currently rates STERIS Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is STE's P/E ratio?: STERIS trades at a trailing price-to-earnings ratio of 23.2.
When does STE report earnings?: STERIS's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $2.80.
What is the STE price target?: The median analyst price target from 7 analysts is $269.00, with a range of $232.00 – $275.00.
Is STE Shariah compliant?: Nama's AAOIFI-style screen reads STERIS as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does STE pay a dividend?: Yes — STERIS's dividend yield is 1.1%.